EZH2 has been shown to downregulate the transcription of cancer suppressor genes and control tumor cell proliferation, migration, and invasive ability by catalyzing H3K27me3.[16] In stem cell research, EZH2 leads to Runx2 inhibition and exerts a negative effect on osteogenic differentiation.[17] Hence, CGRP is assumed to reduce methylation levels of H3K27me3 and accelerate the transcription of osteogenic genes by balancing KDM6A and EZH2 in this study. Here, KDM6A is linked to cancer.